Phase 3 data presented at ACR Convergence 2026 show up to 28.7% weight loss with the triple agonist, alongside sustained knee pain relief.
Philip Conaghan, MBBS, PhD
Advertisement
Director of the NIHR Leeds Biomedical Research Centre; Prof of Musculoskeletal Medicine for University of Leeds, Honorary Consultant Rheumatologist for LTHT; NIHR Senior Investigator Emeritus
Articles by Philip Conaghan, MBBS, PhD
Conaghan discussed the potential of StEPP as a measure in clinical trials.
Conaghan discussed the potential of LEVI-04 for knee osteoarthritis at ACR 2025.
Conaghan discussed findings from the ENX-CL-05-001 phase 2a trial at the ACR Convergence.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Rheumatology Live
1
CD19 CAR T Shows Early Remission in Treatment-Refractory RA
2
Retatrutide Reduces Knee Osteoarthritis Pain in TRIUMPH-4, TRIUMPH-1-OA
3
Retatrutide Cuts Knee OA Pain, With Philip Conaghan, MBBS, PhD
4
Bimekizumab Leads New Wave of PsA Comparative Data: Philip Mease, MD
5